NTRB
Price
$9.11
Change
-$0.80 (-8.07%)
Updated
Jul 7, 11:29 AM (EDT)
Capitalization
110.3M
86 days until earnings call
STOK
Price
$11.63
Change
+$0.15 (+1.31%)
Updated
Jul 7, 01:49 PM (EDT)
Capitalization
626.77M
35 days until earnings call
Interact to see
Advertisement

NTRB vs STOK

Header iconNTRB vs STOK Comparison
Open Charts NTRB vs STOKBanner chart's image
Nutriband
Price$9.11
Change-$0.80 (-8.07%)
Volume$128
Capitalization110.3M
Stoke Therapeutics
Price$11.63
Change+$0.15 (+1.31%)
Volume$1K
Capitalization626.77M
NTRB vs STOK Comparison Chart in %
Loading...
NTRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NTRB vs. STOK commentary
Jul 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTRB is a Buy and STOK is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 07, 2025
Stock price -- (NTRB: $9.91 vs. STOK: $11.48)
Brand notoriety: NTRB and STOK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NTRB: 169% vs. STOK: 30%
Market capitalization -- NTRB: $110.3M vs. STOK: $626.77M
NTRB [@Biotechnology] is valued at $110.3M. STOK’s [@Biotechnology] market capitalization is $626.77M. The market cap for tickers in the [@Biotechnology] industry ranges from $316.35B to $0. The average market capitalization across the [@Biotechnology] industry is $2.39B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTRB’s FA Score shows that 0 FA rating(s) are green whileSTOK’s FA Score has 1 green FA rating(s).

  • NTRB’s FA Score: 0 green, 5 red.
  • STOK’s FA Score: 1 green, 4 red.
According to our system of comparison, STOK is a better buy in the long-term than NTRB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTRB’s TA Score shows that 3 TA indicator(s) are bullish while STOK’s TA Score has 2 bullish TA indicator(s).

  • NTRB’s TA Score: 3 bullish, 4 bearish.
  • STOK’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, NTRB is a better buy in the short-term than STOK.

Price Growth

NTRB (@Biotechnology) experienced а +26.56% price change this week, while STOK (@Biotechnology) price change was -3.04% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.51%. For the same industry, the average monthly price growth was +14.00%, and the average quarterly price growth was -0.49%.

Reported Earning Dates

NTRB is expected to report earnings on Oct 01, 2025.

STOK is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+5.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
STOK($627M) has a higher market cap than NTRB($110M). NTRB YTD gains are higher at: 110.403 vs. STOK (4.080). STOK has higher annual earnings (EBITDA): 40.3M vs. NTRB (-9.68M). STOK has more cash in the bank: 357M vs. NTRB (2.96M). NTRB has less debt than STOK: NTRB (282K) vs STOK (2.35M). STOK has higher revenues than NTRB: STOK (191M) vs NTRB (2.4M).
NTRBSTOKNTRB / STOK
Capitalization110M627M18%
EBITDA-9.68M40.3M-24%
Gain YTD110.4034.0802,706%
P/E RatioN/A14.00-
Revenue2.4M191M1%
Total Cash2.96M357M1%
Total Debt282K2.35M12%
FUNDAMENTALS RATINGS
NTRB vs STOK: Fundamental Ratings
NTRB
STOK
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
52
Fair valued
PROFIT vs RISK RATING
1..100
94100
SMR RATING
1..100
9841
PRICE GROWTH RATING
1..100
3640
P/E GROWTH RATING
1..100
10033
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

STOK's Valuation (52) in the null industry is in the same range as NTRB (78). This means that STOK’s stock grew similarly to NTRB’s over the last 12 months.

NTRB's Profit vs Risk Rating (94) in the null industry is in the same range as STOK (100). This means that NTRB’s stock grew similarly to STOK’s over the last 12 months.

STOK's SMR Rating (41) in the null industry is somewhat better than the same rating for NTRB (98). This means that STOK’s stock grew somewhat faster than NTRB’s over the last 12 months.

NTRB's Price Growth Rating (36) in the null industry is in the same range as STOK (40). This means that NTRB’s stock grew similarly to STOK’s over the last 12 months.

STOK's P/E Growth Rating (33) in the null industry is significantly better than the same rating for NTRB (100). This means that STOK’s stock grew significantly faster than NTRB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NTRBSTOK
RSI
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
89%
Momentum
ODDS (%)
Bullish Trend 5 days ago
84%
Bearish Trend 5 days ago
83%
MACD
ODDS (%)
Bullish Trend 5 days ago
71%
Bearish Trend 5 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 5 days ago
77%
Bearish Trend 5 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 5 days ago
81%
Bullish Trend 5 days ago
84%
Advances
ODDS (%)
Bullish Trend 6 days ago
81%
Bullish Trend 12 days ago
86%
Declines
ODDS (%)
Bearish Trend 27 days ago
88%
Bearish Trend 5 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
89%
Bearish Trend 5 days ago
90%
Aroon
ODDS (%)
N/A
Bullish Trend 5 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
NTRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CWYUF18.930.11
+0.57%
SmartCentres Real Estate Investment Trust
FFDF35.00N/A
N/A
FFD Financial Corp.
JDEPF27.75N/A
N/A
JDE Peet's NV
FMCCM18.25N/A
N/A
Freddie Mac
MCEM237.00-0.98
-0.41%
Monarch Cement Co. (The)

NTRB and

Correlation & Price change

A.I.dvisor tells us that NTRB and SONN have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NTRB and SONN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTRB
1D Price
Change %
NTRB100%
-7.56%
SONN - NTRB
29%
Poorly correlated
-5.54%
RARE - NTRB
27%
Poorly correlated
+1.14%
REPL - NTRB
27%
Poorly correlated
-1.57%
STOK - NTRB
27%
Poorly correlated
-0.61%
DNLI - NTRB
25%
Poorly correlated
-1.41%
More

STOK and

Correlation & Price change

A.I.dvisor indicates that over the last year, STOK has been loosely correlated with IDYA. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if STOK jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STOK
1D Price
Change %
STOK100%
-0.61%
IDYA - STOK
53%
Loosely correlated
+0.82%
NRIX - STOK
52%
Loosely correlated
+2.33%
IMNM - STOK
51%
Loosely correlated
+2.43%
RNA - STOK
50%
Loosely correlated
-0.65%
DNLI - STOK
50%
Loosely correlated
-1.41%
More